• Recently a Phase III study demonstrated that alectinib

  2024-06-05

  

  Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat

• While the mechanisms by which ALDH regulates cardiac respons

  2024-06-05

  

  While the mechanisms by which ALDH2 regulates cardiac responses to pathological stress remain unclear, the capillary rarefaction found in pressure-overloaded ALDH2 Tg hearts provides potential clues. Loss of capillary density and diminished endothelial function occur in pathological hypertrophy [46]

• It is well known that TCDD is the most

  2024-06-05

  

  It is well-known that TCDD is the most potent ligand of AhR and it regulates gene expression, such as CYP1A1, via activation of AhR (Mimura and Fujii-Kuriyama, 2003). Besides Tomblin et al. (2016) have recently shown that TCDD via AhR regulated L-type amino EMD638683 transporter 1 expression in MCF

• br AChE variants and their

  2024-06-04

  

  AChE variants and their functions The AChE gene generates several splice variants of AChE which are designated as hydrophobic (H), readthrough (R) and tailed (T) forms differing in membrane association and also localisation on a tissue and sub-cellular level. They all undergo significant posttran

• An alternative to the agonist or antagonist potential

  2024-06-04

  

  An alternative to the agonist or antagonist potential in drug discovery is the positive allosteric modulator (PAM) approach, which can augment the normal processes of neurotransmission as opposed to directly replacing or antagonizing them. PAMs are thought to bind to sites that are distinct from the

• What can we learn about the anticancer

  2024-06-04

  

  What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito

• Although several different membrane estrogen receptors have

  2024-06-04

  

  Although several different membrane estrogen receptors have been reported (Qiu et al., 2008; Revankar et al., 2005), a large percentage of membrane-initiated steroid hormone signaling appears to be performed by a subpopulation of the same receptors that act in the nucleus. Specifically, estrogen rec

• ASK has been identified as an ASK

  2024-06-04

  

  ASK2 has been identified as an ASK1 binding protein (Wang et al., 1998). ASK1 supports the stability and active configuration of ASK2 in the heteromeric complex, while ASK2 has been found to activate ASK1 by direct phosphorylation (Takeda et al., 2007). Unlike ASK1, which is ubiquitously expressed i

• br Emerging Vascular Mechanisms of AA Therapy Resistance Exp

  2024-06-04

  

  Emerging Vascular Mechanisms of AA Therapy Resistance Experimental and clinical evidence indicates that physiological angiogenesis generates blood vessels capable of restoring perfusion [1], whereas tumoral angiogenesis gives rise to vessels that are structurally and functionally abnormal, therei

• The first evidence in supporting

  2024-06-04

  

  The first evidence in supporting the hypothesis that MAS receptors mediate the effects elicited by AT1 antagonists was provided by Iwai et al. (2012). The authors found that AT1 receptors triggers neointima formation after polyethylene-cuff placement around mouse femoral artery by reducing local ACE

• The proposed formulation is however challenging to solve

  2024-06-03

  

  The proposed formulation is, however, challenging to solve since the structured sparsity-inducing norms are non-smooth. In order to solve the new objective function, we consider two different approaches: proximal averaging, which takes the average the solutions from the proximal operator for the ind

• Active SI behavior was dose dependently

  2024-06-03

  

  Active SI behavior was dose-dependently affected by PACAP treatment (F3,25 = 14.42, p Etoposide 1 week later (F3,20 = 8.93, p significantly more time engaging in active SI behaviors compared with rats treated with VEH (p hypothesis that PACAP causes disruptions in posterror adjustments that are sim

• br Results br Discussion The present study uncovers a

  2024-06-03

  

  Results Discussion The present study uncovers a role of calpain, a family of calcium-dependent protease, in regulating postsynaptic differentiation at the NMJ. Cholinergic activation stimulates calpain, whose inhibition stabilizes AChR clusters in cultured muscle kanamycin australia and in ag

• L-365,260 receptor The difficulty of characterizing nAChRs i

  2024-06-03

  

  The difficulty of characterizing nAChRs in the central nervous system is also exemplified by early observations that nicotine caused no detectable effect when applied on a brain slice and it is only with the focal and high time resolution of more recent experiments that the effects of nicotinic neur

• Whereas more research is needed

  2024-06-03

  

  Whereas more research is needed to identify the precise mechanism by which FIN exerts its antidyskinetic effect, the ws3 that it can negatively modulate dopaminergic transmission is also supported by our previous findings. Indeed, we have previously shown that FIN completely reversed the behavioral

15983 records 116/1066 page Previous Next First page 上5页 116117118119120 下5页 Last page